home / stock / lumo / lumo quote
Last: | $1.47 |
---|---|
Change Percent: | -7.53% |
Open: | $1.57 |
Close: | $1.47 |
High: | $1.57 |
Low: | $1.45 |
Volume: | 20,112 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.47 | $1.57 | $1.47 | $1.57 | $1.45 | 20,112 | 07-22-2024 |
$1.46 | $1.48 | $1.46 | $1.54 | $1.46 | 9,455 | 07-19-2024 |
$1.45 | $1.52 | $1.45 | $1.56 | $1.399 | 54,185 | 07-18-2024 |
$1.5 | $1.56 | $1.5 | $1.57 | $1.4449 | 59,566 | 07-17-2024 |
$1.54 | $1.52 | $1.54 | $1.69 | $1.39 | 76,832 | 07-16-2024 |
$1.5 | $1.65 | $1.5 | $1.695 | $1.5 | 16,153 | 07-15-2024 |
$1.65 | $1.87 | $1.65 | $1.87 | $1.55 | 83,639 | 07-12-2024 |
$1.77 | $1.68 | $1.77 | $1.84 | $1.64 | 52,402 | 07-11-2024 |
$1.77 | $1.905 | $1.77 | $1.905 | $1.3701 | 63,211 | 07-10-2024 |
$1.78 | $2.108 | $1.78 | $2.15 | $1.75 | 230,641 | 07-09-2024 |
$2.18 | $2.15 | $2.18 | $2.23 | $2.15 | 2,001 | 07-08-2024 |
$2.21 | $2.17 | $2.21 | $2.21 | $2.09 | 2,380 | 07-05-2024 |
$2.2 | $2.24 | $2.2 | $2.275 | $2.2 | 2,183 | 07-04-2024 |
$2.2 | $2.24 | $2.2 | $2.275 | $2.2 | 2,183 | 07-03-2024 |
$2.27 | $2.32 | $2.27 | $2.32 | $2.17 | 12,201 | 07-02-2024 |
$2.263 | $2.25 | $2.263 | $2.38 | $2.25 | 23,985 | 07-01-2024 |
$2.32 | $2.25 | $2.32 | $2.32 | $2.25 | 952 | 06-28-2024 |
$2.2512 | $2.2501 | $2.2512 | $2.2512 | $2.2301 | 2,528 | 06-27-2024 |
$2.255 | $2.25 | $2.255 | $2.28 | $2.25 | 3,039 | 06-26-2024 |
$2.24 | $2.34 | $2.24 | $2.34 | $2.2105 | 3,925 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...